ALERT for all players using Supplements - Higenamine

FIBA has learned that an alarmingly high number of Adverse Analytical Findings (AAF) for the Prohibited Substance ‘Higenamine’ were recently reported in Basketball. These findings were reported from various geographical regions. 

We strongly encourage you to carefully review the present document, which contains important information and preventive measures to avoid jeopardising your career.

WARNING: Cannabis 

Please be aware that consumption out-of-competition can give rise to a positive result several days (or weeks) later. Even if cannabis is legal in your country, positive results usually lead a period of ineligibility (click here for examples). 

WADA 2020 List of Prohibited Substances and Methods

By the present we would like to inform all players, team doctors and other basketball stakeholders that the World Anti-Doping Agency (WADA) has published the 2020 List of Prohibited Substances. 

The list came into effect on 01 January 2020.

Under the FIBA Internal Regulations governing Anti-Doping, it is each player’s personal duty to ensure that no Prohibited Substance enters his or her body.

Therefore, it is essential that all players and support personnel review carefully the 2020 Prohibited List, particularly in cases where they intent to use supplements or medication.


Competing on an even playing field, where hard work, training and talent are the fundamental difference between winning and losing, holds a central place within the sporting ethos. The practice of trying to gain an unfair advantage through dishonest means is as old as sport itself. It remains a never-ending battle, but one that FIBA takes extremely seriously.

Since the 1980s, FIBA has regularly and in increasing numbers performed doping controls at its Championships. As a signatory of the WADA World Anti-Doping Code, first introduced in 2004, FIBA remains strongly committed to the fight against doping in basketball.


FIBA Anti-Doping activities cover the search for - and measures against- basketball players using banned substances and methods. Also, and just as importantly, they focus on actively promoting awareness of doping related issues, whether from a sporting or a health perspective.

This section contains all information related to FIBA’s anti-doping activities, whether from a player, team or medical staff point of view. It covers all regulations and procedures, outlined in the FIBA Internal Regulations governing Anti-Doping (Book 4) and aligned with the WADA Code, as well as providing practical information and details about FIBA’s Clean Game awareness programme.

FIBA's Responsibilities

FIBA is taking care of the following Anti-doping related tasks:

  • Organisation of doping controls for all FIBA competitions
  • Management of FIBA’s Out-of-Competition Testing System through its Registered Testing Pool
  • Results management in case of Adverse Analytical Findings (AAF)and review of national Anti-Doping Rule Violations (ADRV)
  • Management of Therapeutic Use Exemptions (TUEs)
  • Production and distribution of anti-doping material for doping controls and educational programmes
  • Cooperation and coordination with the Anti-Doping Organization involved in Basketball (National Federations, National Anti-Doping Organizations, professional leagues)

General testing principles

For doping controls FIBA makes the common distinction between In-Competition testing and Out-of-Competition testing.

In-Competition testing is currently defined as follows:

"In-Competition testing shall apply and is defined as any doping control of which the player is notified from 12 hours prior to an official game through to and including 4 hours after the game."

Out-of-Competition testing refers to all tests that are not defined as In-Competition. While it may apply to any basketball player of any league affiliated through its National Federation to FIBA, Out-of-Competition testing is mainly implemented through the Registered Testing Pool (RTP).

Please note that the above information is for basic informative purposes only. For the exact, legally-binding and most up-to-date regulations on Anti-Doping, always refer to the FIBA Internal Regulations governing Anti-Doping (Book 4).


In-Competition Doping Control organized by FIBA between 2010-2016

2010 2011 2012 2013 2014 2015 2016
466 492 404 486 648 542 470


Out-of-Competition Doping Control organized by FIBA between 2010-2016

2010 2011 2012 2013 2014 2015 2016
64 28 33 52 112 55 83


FIBA Results Management Statistics 2010-2016

  2010 2011 2012 2013 2014 2015 2016
Atypical Findings 2 3 0 7 6 8 11
Adverse Analytical Findings (AAF) 10 13 16 1 3 21* 6
Anti-Doping Rule Violations (ADRV) resulting from an AAF 10 13 16 1 1 6** 2
Non-analytical AAF 0 0 0 2 0 0 0


* includes 19 AAFs which resulted from Clenbuterol contaminated meat

** includes 5 cases where the Results Management Authority has been delegated to FIBA by other Anti-Doping Organisations (ADO)